Introduction Exenatide is an incretin-based antidiabetic drug classified as a glucagon-like peptide-1 (GLP-1) receptor agonist. It is used in the management of type 2 diabetes mellitus to improve glycemic control, particularly in patients with inadequate response to oral antidiabetic agents. Exenatide is exam-relevant because it mimics endogenous GLP-1, enhances glucose-dependent insulin secretion, promotes weight loss, … Read more
Introduction Liraglutide is a long-acting GLP‑1 receptor agonist, injected once daily. It’s used for type 2 diabetes mellitus (T2DM) and chronic weight management, and also approved for reducing cardiovascular risk in patients with T2DM and established heart disease. It mimics the effects of endogenous GLP‑1 to improve glycemic control and promote satiety. Step-by-Step Mechanism of … Read more
Introduction Semaglutide (Ozempic for diabetes; Wegovy for obesity) is a GLP‑1 receptor agonist used for type 2 diabetes mellitus management and chronic weight loss. It mimics the incretin hormone glucagon‑like peptide‑1 (GLP‑1), leading to improved glycemic control, reduced appetite, delayed gastric emptying, and favorable effects on cardiovascular risk. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value … Read more
